Circulating tumour DNA: a challenging innovation to develop “precision onco-surgery” in pancreatic adenocarcinoma

[1]  W. Bamlet,et al.  High Detection Rates of Pancreatic Cancer Across Stages by Plasma Assay of Novel Methylated DNA Markers and CA19-9 , 2021, Clinical Cancer Research.

[2]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[3]  Shin-E Wang,et al.  Circulating Cell-Free DNA in Pancreatic Head Adenocarcinoma Undergoing Pancreaticoduodenectomy , 2021, Pancreas.

[4]  S. Jeffrey,et al.  Liquid biopsy enters the clinic — implementation issues and future challenges , 2021, Nature Reviews Clinical Oncology.

[5]  H. Nagano,et al.  Combination of CA19-9 and Blood Free-Circulating Methylated RUNX3 May Be Useful to Diagnose Stage I Pancreatic Cancer , 2021, Oncology.

[6]  Shinya Takahashi,et al.  Clinical Implications of Pre- and Postoperative Circulating Tumor DNA in Patients with Resected Pancreatic Ductal Adenocarcinoma , 2020, Annals of Surgical Oncology.

[7]  M. Ishida,et al.  GNAS mutation detection in circulating cell-free DNA is a specific predictor for intraductal papillary mucinous neoplasms of the pancreas, especially for intestinal subtype , 2020, Scientific Reports.

[8]  M. Boerries,et al.  Longitudinal analysis of cell-free mutated KRAS and CA 19–9 predicts survival following curative resection of pancreatic cancer , 2020, BMC cancer.

[9]  F. Yang,et al.  Non-invasive lung cancer diagnosis and prognosis based on multi-analyte liquid biopsy , 2020, medRxiv.

[10]  T. Bauernhofer,et al.  A Multi-Analyte Approach for Improved Sensitivity of Liquid Biopsies in Prostate Cancer , 2020, Cancers.

[11]  K. Honda,et al.  Use of Biomarkers and Imaging for Early Detection of Pancreatic Cancer , 2020, Cancers.

[12]  H. Aburatani,et al.  A novel sensitive detection method for DNA methylation in circulating free DNA of pancreatic cancer , 2020, PloS one.

[13]  J. Vandesompele,et al.  Genome-wide study of the effect of blood collection tubes on the cell-free DNA methylome , 2020, bioRxiv.

[14]  A. Saraya,et al.  Clinical significance of promoter methylation status of tumor suppressor genes in circulating DNA of pancreatic cancer patients , 2020, Journal of Cancer Research and Clinical Oncology.

[15]  Helen M Moore,et al.  Harmonizing Cell-Free DNA Collection and Processing Practices through Evidence-Based Guidance , 2020, Clinical Cancer Research.

[16]  A. Sauvanet,et al.  Vascular Resection for Pancreatic Cancer: 2019 French Recommendations Based on a Literature Review From 2008 to 6-2019 , 2020, Frontiers in Oncology.

[17]  G. Jin,et al.  Preoperative detection of KRAS G12D mutation in ctDNA is a powerful predictor for early recurrence of resectable PDAC patients , 2020, British Journal of Cancer.

[18]  A. Jemal,et al.  Cancer statistics, 2020 , 2020, CA: a cancer journal for clinicians.

[19]  T. Rikiyama,et al.  Longitudinal monitoring of KRAS-mutated circulating tumor DNA enables the prediction of prognosis and therapeutic responses in patients with pancreatic cancer , 2019, PloS one.

[20]  R. Kurzrock,et al.  Clinical correlates of blood-derived circulating tumor DNA in pancreatic cancer , 2019, Journal of Hematology & Oncology.

[21]  K. Sugimori,et al.  Quantitative monitoring of circulating tumor DNA in patients with advanced pancreatic cancer undergoing chemotherapy , 2019, Cancer science.

[22]  S. Dabernat,et al.  High Clinical Value of Liquid Biopsy to Detect Circulating Tumor Cells and Tumor Exosomes in Pancreatic Ductal Adenocarcinoma Patients Eligible for Up-Front Surgery , 2019, Cancers.

[23]  B. Vogelstein,et al.  Circulating tumor DNA as a potential marker of adjuvant chemotherapy benefit following surgery for localised pancreatic cancer. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[24]  M. J. van de Vijver,et al.  Circulating tumor DNA quantity is related to tumor volume and both predict survival in metastatic pancreatic ductal adenocarcinoma , 2019, International journal of cancer.

[25]  S. Gulati,et al.  Analysis of circulating cell-free DNA identifies KRAS copy number gain and mutation as a novel prognostic marker in Pancreatic cancer , 2019, Scientific Reports.

[26]  S. Dabernat,et al.  CD63-GPC1-Positive Exosomes Coupled with CA19-9 Offer Good Diagnostic Potential for Resectable Pancreatic Ductal Adenocarcinoma , 2019, Translational oncology.

[27]  S. Dabernat,et al.  Liquid Biopsy Approach for Pancreatic Ductal Adenocarcinoma , 2019, Cancers.

[28]  Lisa M Haley,et al.  Circulating Tumor DNA as a Clinical Test in Resected Pancreatic Cancer , 2019, Clinical Cancer Research.

[29]  L. Wood,et al.  Promoter methylation of ADAMTS1 and BNC1 as potential biomarkers for early detection of pancreatic cancer in blood , 2019, Clinical epigenetics.

[30]  Dylan T Burnette,et al.  Reassessment of Exosome Composition , 2019, Cell.

[31]  C. Yau,et al.  Immunophenotypes of pancreatic ductal adenocarcinoma: Meta‐analysis of transcriptional subtypes , 2019, International journal of cancer.

[32]  Prashanth Rawla,et al.  Epidemiology of Pancreatic Cancer: Global Trends, Etiology and Risk Factors , 2019, World journal of oncology.

[33]  Thierry Lecomte,et al.  FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer , 2018, The New England journal of medicine.

[34]  V. Heinemann,et al.  Repeated mutKRAS ctDNA measurements represent a novel and promising tool for early response prediction and therapy monitoring in advanced pancreatic cancer , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[35]  D. Franchimont,et al.  Stratification of Pancreatic Ductal Adenocarcinomas Based on Tumor and Microenvironment Features. , 2018, Gastroenterology.

[36]  J. McPherson,et al.  Sensitive tumour detection and classification using plasma cell-free DNA methylomes , 2018, Nature.

[37]  J. Joo,et al.  Prognostic Implications of Multiplex Detection of KRAS Mutations in Cell-Free DNA from Patients with Pancreatic Ductal Adenocarcinoma. , 2018, Clinical chemistry.

[38]  Ludmila V. Danilova,et al.  Detection and localization of surgically resectable cancers with a multi-analyte blood test , 2018, Science.

[39]  T. Hibi,et al.  KRAS mutations in cell-free DNA from preoperative and postoperative sera as a pancreatic cancer marker: a retrospective study , 2018, British Journal of Cancer.

[40]  P. Madsen,et al.  Cell-free DNA promoter hypermethylation in plasma as a predictive marker for survival of patients with pancreatic adenocarcinoma , 2017, Oncotarget.

[41]  S. Monaco,et al.  Preoperative next-generation sequencing of pancreatic cyst fluid is highly accurate in cyst classification and detection of advanced neoplasia , 2017, Gut.

[42]  M. Makary,et al.  Combined circulating tumor DNA and protein biomarker-based liquid biopsy for the earlier detection of pancreatic cancers , 2017, Proceedings of the National Academy of Sciences.

[43]  Steven J. M. Jones,et al.  Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma. , 2017, Cancer cell.

[44]  M. Wagner,et al.  CT evaluation after neoadjuvant FOLFIRINOX chemotherapy for borderline and locally advanced pancreatic adenocarcinoma , 2017, European Radiology.

[45]  S. Hanash,et al.  High prevalence of mutant KRAS in circulating exosome-derived DNA from early-stage pancreatic cancer patients , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[46]  James D. Brenton,et al.  Liquid biopsies come of age: towards implementation of circulating tumour DNA , 2017, Nature Reviews Cancer.

[47]  Valérie Taly,et al.  Plasma Circulating Tumor DNA in Pancreatic Cancer Patients Is a Prognostic Marker , 2016, Clinical Cancer Research.

[48]  Y. Rozenholc,et al.  Base-Position Error Rate Analysis of Next-Generation Sequencing Applied to Circulating Tumor DNA in Non-Small Cell Lung Cancer: A Prospective Study , 2016, PLoS medicine.

[49]  P. Brennan,et al.  KRAS mutations in blood circulating cell-free DNA: a pancreatic cancer case-control , 2016, Oncotarget.

[50]  J. Ferlay,et al.  More deaths from pancreatic cancer than breast cancer in the EU by 2017 , 2016, Acta oncologica.

[51]  M. Büchler,et al.  Detection of Hot-Spot Mutations in Circulating Cell-Free DNA From Patients With Intraductal Papillary Mucinous Neoplasms of the Pancreas. , 2016, Gastroenterology.

[52]  P. B. Gahan,et al.  Origins, structures, and functions of circulating DNA in oncology , 2016, Cancer and Metastasis Reviews.

[53]  E. Hiyama,et al.  Prognostic value of circulating tumour DNA in patients undergoing curative resection for pancreatic cancer , 2016, British Journal of Cancer.

[54]  Ash A. Alizadeh,et al.  Integrated digital error suppression for improved detection of circulating tumor DNA , 2016, Nature Biotechnology.

[55]  R. Gibbs,et al.  Genomic analyses identify molecular subtypes of pancreatic cancer , 2016, Nature.

[56]  L. Buscail,et al.  Targeting KRAS for diagnosis, prognosis, and treatment of pancreatic cancer: Hopes and realities. , 2016, European journal of cancer.

[57]  H. Ueno,et al.  Clinical utility of circulating tumor DNA for molecular assessment in pancreatic cancer , 2015, Scientific Reports.

[58]  Jin-Young Jang,et al.  A combination of molecular markers and clinical features improve the classification of pancreatic cysts. , 2015, Gastroenterology.

[59]  N. Malats,et al.  Circulating tumor cells (CTC) and KRAS mutant circulating free DNA (cfDNA) detection in peripheral blood as biomarkers in patients diagnosed with exocrine pancreatic cancer , 2015, BMC Cancer.

[60]  Katherine Van Loon,et al.  Cell-Free DNA Next-Generation Sequencing in Pancreatobiliary Carcinomas. , 2015, Cancer discovery.

[61]  R. Scharpf,et al.  Clinical implications of genomic alterations in the tumour and circulation of pancreatic cancer patients , 2015, Nature Communications.

[62]  K. Nouso,et al.  Detection of K‐ras gene mutation by liquid biopsy in patients with pancreatic cancer , 2015, Cancer.

[63]  J. Kench,et al.  Whole genomes redefine the mutational landscape of pancreatic cancer , 2015, Nature.

[64]  Ed Yong,et al.  Cancer biomarkers: Written in blood , 2014, Nature.

[65]  L. Diaz,et al.  Liquid biopsies: genotyping circulating tumor DNA. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[66]  M. Choti,et al.  Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies , 2014, Science Translational Medicine.

[67]  Channing J Der,et al.  KRAS: feeding pancreatic cancer proliferation. , 2014, Trends in biochemical sciences.

[68]  Ash A. Alizadeh,et al.  An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage , 2013, Nature Medicine.

[69]  David Goldstein,et al.  Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. , 2013, The New England journal of medicine.

[70]  B. Lapuyade,et al.  An evaluation of the accuracy of CT when determining resectability of pancreatic head adenocarcinoma after neoadjuvant treatment. , 2013, European journal of radiology.

[71]  Valérie Taly,et al.  Detecting biomarkers with microdroplet technology. , 2012, Trends in molecular medicine.

[72]  U. Ballehaninna,et al.  The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal. , 2012, Journal of gastrointestinal oncology.

[73]  D. Bar-Sagi,et al.  RAS oncogenes: weaving a tumorigenic web , 2011, Nature Reviews Cancer.

[74]  Pierre Michel,et al.  FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. , 2011, The New England journal of medicine.

[75]  Mariza de Andrade,et al.  Leukocyte DNA Methylation Signature Differentiates Pancreatic Cancer Patients from Healthy Controls , 2011, PloS one.

[76]  M. Nowak,et al.  Distant Metastasis Occurs Late during the Genetic Evolution of Pancreatic Cancer , 2010, Nature.

[77]  R. Abrams,et al.  Differential methylation of cell‐free circulating DNA among patients with pancreatic cancer versus chronic pancreatitis , 2010, Cancer.

[78]  H. Oettle,et al.  Follow-Up Study of K-ras Mutations in the Plasma of Patients With Pancreatic Cancer: Correlation With Clinical Features and Carbohydrate Antigen 19-9 , 2009, Pancreas.

[79]  D. Scholtens,et al.  Methylation profile of circulating plasma DNA in patients with pancreatic cancer , 2009, Journal of surgical oncology.

[80]  R. Hruban,et al.  Emerging molecular biology of pancreatic cancer. , 2008, Gastrointestinal cancer research : GCR.

[81]  M. Goggins.  Molecular markers of early pancreatic cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[82]  R. DePinho,et al.  Pancreatic cancer biology and genetics , 2002, Nature Reviews Cancer.

[83]  A. Feinberg,et al.  DNA methylation and genomic imprinting: insights from cancer into epigenetic mechanisms. , 2002, Seminars in cancer biology.

[84]  P. Ruszniewski,et al.  Differential diagnosis between chronic pancreatitis and pancreatic cancer: value of the detection of KRAS2 mutations in circulating DNA , 2002, British Journal of Cancer.

[85]  J. Furuse,et al.  CA 19-9 in evaluating the response to chemotherapy in advanced pancreatic cancer. , 1997, Hepato-gastroenterology.

[86]  B. Shapiro,et al.  Determination of circulating DNA levels in patients with benign or malignant gastrointestinal disease , 1983, Cancer.

[87]  H. Kocher,et al.  Pancreatic Cancer , 2019, Methods in Molecular Biology.

[88]  Shinya Takahashi,et al.  Comparison of the prognostic impact of pre- and post-operative CA19-9, SPan-1, and DUPAN-II levels in patients with pancreatic carcinoma. , 2017, Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.].

[89]  Jeffrey W. Clark,et al.  "Radiological and Surgical Implications of Neoadjuvant Treatment With FOLFIRINOX for Locally Advanced and Borderline Resectable Pancreatic Cancer." , 2017, Annals of surgery.